// App-Quantinova.ai

POS0676 (2022) : EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY

Researchers

Presenter

  • D. Aletaha

Principal Investigators

  • R. Westhovens

  • B. Combe

  • J. E. Gottenberg

  • M. H. Buch

  • R. Caporali

  • J. A. Gomez-Puerta

  • P. Van Hoek

  • V. Rajendran

  • P. J. Stiers

  • T. Hendrikx

  • G. R. Burmester

  • Y. Tanaka

Medical Centers

  • Medical University of Vienna, Department of Internal Medicine III, Division of Rheumatology, 1090, Austria

  • University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium

  • Montpellier University, Department of Rheumatology, Montpellier, France

  • Strasbourg University Hospital, Rheumatology Department, Strasbourg, France

  • University of Manchester, Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Medicine & Health, Manchester, United Kingdom

  • University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy

  • Hospital Clinic de Barcelona, Department of Radiology, Barcelona, Spain

  • Galapagos NV, Development, Mechelen, Belgium

  • Galapagos NV, Bioinformatics, Mechelen, Belgium

  • Galapagos NV, Medical Affairs, Leiden, Netherlands

  • Charite University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany.

  • University of Occupational and Environmental Health, Kitakyushu, Japan

Locations

  • Austria

  • Belgium

  • France

  • United Kingdom

  • Italy

  • Spain

  • Netherlands

  • Germany

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT03025308

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved